Kenneth Offit

List of Publications by Year in Descending Order

380 papers	29,460 citations	97 h-index	161 g-index
395 ext. papers	35,230 ext. citations	10.6 avg, IF	6.35 L-index

#	Paper	IF	Citations
380	Common variants in breast cancer risk loci predispose to distinct tumor subtypes.. *Breast Cancer Research*, **2022**, 24, 2	8.3	3
379	The context-specific role of germline pathogenicity in tumorigenesis. *Nature Genetics*, **2021**, 53, 1577-1586	38.3	6
378	Inherited TP53 Variants and Risk of Prostate Cancer. *European Urology*, **2021**,	10.2	4
377	Targeted BRCA1/2 population screening among Ashkenazi Jewish individuals using a web-enabled medical model: An observational cohort study.. *Genetics in Medicine*, **2021**,	8.1	1
376	Germline RAD51B variants confer susceptibility to breast and ovarian cancers deficient in homologous recombination. *Npj Breast Cancer*, **2021**, 7, 135	7.8	0
375	Clonal hematopoiesis is associated with risk of severe Covid-19. *Nature Communications*, **2021**, 12, 5975	17.4	12
374	Facilitated cascade testing (FaCT): a randomized controlled trial. *International Journal of Gynecological Cancer*, **2021**, 31, 779-783	3.5	1
373	Sequencing at lymphoid neoplasm susceptibility loci maps six myeloma risk genes. *Human Molecular Genetics*, **2021**, 30, 1142-1153	5.6	
372	Response to Li and Hopper. *American Journal of Human Genetics*, **2021**, 108, 527-529	11	1
371	The role of digital tools in the delivery of genomic medicine: enhancing patient-centered care. *Genetics in Medicine*, **2021**, 23, 1086-1094	8.1	3
370	Circulating Levels of Testosterone, Sex Hormone Binding Globulin and Colorectal Cancer Risk: Observational and Mendelian Randomization Analyses. *Cancer Epidemiology Biomarkers and Prevention*, **2021**, 30, 1336-1348	4	3
369	Novel ultra-rare exonic variants identified in a founder population implicate cadherins in schizophrenia. *Neuron*, **2021**, 109, 1465-1478.e4	13.9	8
368	The predictive ability of the 313 variant-based polygenic risk score for contralateral breast cancer risk prediction in women of European ancestry with a heterozygous BRCA1 or BRCA2 pathogenic variant. *Genetics in Medicine*, **2021**, 23, 1726-1737	8.1	2
367	Prevalence of Germline Alterations on Targeted Tumor-Normal Sequencing of Esophagogastric Cancer. *JAMA Network Open*, **2021**, 4, e2114753	10.4	4
366	Functional annotation of the 2q35 breast cancer risk locus implicates a structural variant in influencing activity of a long-range enhancer element. *American Journal of Human Genetics*, **2021**, 108, 1190-1203	11	1
365	Identifying Novel Susceptibility Genes for Colorectal Cancer Risk From a Transcriptome-Wide Association Study of 125,478 Subjects. *Gastroenterology*, **2021**, 160, 1164-1178.e6	13.3	15
364	Characterization and Clinical Outcomes of DNA Mismatch Repair-deficient Small Bowel Adenocarcinoma. *Clinical Cancer Research*, **2021**, 27, 1429-1437	12.9	9

363	Targeting Germline- and Tumor-Associated Nucleotide Excision Repair Defects in Cancer. *Clinical Cancer Research*, **2021**, 27, 1997-2010	12.9	2
362	Genetically predicted circulating concentrations of micronutrients and risk of colorectal cancer among individuals of European descent: a Mendelian randomization study. *American Journal of Clinical Nutrition*, **2021**, 113, 1490-1502	7	5
361	Genome-wide homozygosity and risk of four non-Hodgkin lymphoma subtypes. *Journal of Translational Genetics and Genomics*, **2021**, 5, 200-217	1.7	
360	A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers. *Nature Communications*, **2021**, 12, 1078	17.4	4
359	Genetic architectures of proximal and distal colorectal cancer are partly distinct. *Gut*, **2021**, 70, 1325-1334	19.2	7
358	Prospective pan-cancer germline testing using MSK-IMPACT informs clinical translation in 751 patients with pediatric solid tumors. *Nature Cancer*, **2021**, 2, 357-365	15.4	23
357	Prevalence and Characterization of Biallelic and Monoallelic and Variant Carriers From a Pan-Cancer Patient Population. *JCO Precision Oncology*, **2021**, 5,	3.6	3
356	Breast and Prostate Cancer Risks for Male BRCA1 and BRCA2 Pathogenic Variant Carriers Using Polygenic Risk Scores. *Journal of the National Cancer Institute*, **2021**,	9.7	3
355	Uptake and acceptability of a mainstreaming model of hereditary cancer multigene panel testing among patients with ovarian, pancreatic, and prostate cancer. *Genetics in Medicine*, **2021**, 23, 2105-2113	8.1	2
354	A Comprehensive Comparison of Early-Onset and Average-Onset Colorectal Cancers. *Journal of the National Cancer Institute*, **2021**,	9.7	12
353	Therapeutic Implications of Germline Testing in Patients With Advanced Cancers. *Journal of Clinical Oncology*, **2021**, 39, 2698-2709	2.2	16
352	Mendelian randomisation study of smoking exposure in relation to breast cancer risk. *British Journal of Cancer*, **2021**, 125, 1135-1145	8.7	0
351	Achieving universal genetic assessment for women with ovarian cancer: Are we there yet? A systematic review and meta-analysis. *Gynecologic Oncology*, **2021**, 162, 506-516	4.9	6
350	Risk-Reducing Bilateral Salpingo-Oophorectomy for Ovarian Cancer: A Review and Clinical Guide for Hereditary Predisposition Genes. *JCO Oncology Practice*, **2021**, OP2100382	2.3	5
349	Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. *Journal of the National Comprehensive Cancer Network: JNCCN*, **2021**, 19, 77-102	7.3	131
348	Hemochromatosis risk genotype is not associated with colorectal cancer or age at its diagnosis.. *Human Genetics and Genomics Advances*, **2020**, 1, 100010	0.8	1
347	Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses. *Nature Genetics*, **2020**, 52, 572-581	36.3	76
346	Protein-altering germline mutations implicate novel genes related to lung cancer development. *Nature Communications*, **2020**, 11, 2220	17.4	6

345	Germline HOXB13 mutations p.G84E and p.R217C do not confer an increased breast cancer risk. *Scientific Reports*, **2020**, 10, 9688	4.9	2
344	Illustrating Cancer Risk: Patient Risk Communication Preferences and Interest regarding a Novel BRCA1/2 Genetic Risk Modifier Test. *Public Health Genomics*, **2020**, 23, 6-19	1.9	4
343	Characterization of the Cancer Spectrum in Men With Germline BRCA1 and BRCA2 Pathogenic Variants: Results From the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). *JAMA Oncology*, **2020**, 6, 1218-1230	13.4	25
342	Transcriptome-wide association study of breast cancer risk by estrogen-receptor status. *Genetic Epidemiology*, **2020**, 44, 442-468	2.6	9
341	Cascading After Peridiagnostic Cancer Genetic Testing: An Alternative to Population-Based Screening. *Journal of Clinical Oncology*, **2020**, 38, 1398-1408	2.2	20
340	Prospective Feasibility Trial of a Novel Strategy of Facilitated Cascade Genetic Testing Using Telephone Counseling. *Journal of Clinical Oncology*, **2020**, 38, 1389-1397	2.2	22
339	11p15.5 epimutations in children with Wilms tumor and hepatoblastoma detected in peripheral blood. *Cancer*, **2020**, 126, 3114-3121	6.4	11
338	Association of Genomic Domains in and with Prostate Cancer Risk and Aggressiveness. *Cancer Research*, **2020**, 80, 624-638	10.1	22
337	NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 1.2020. *Journal of the National Comprehensive Cancer Network: JNCCN*, **2020**, 18, 380-391	7.3	171
336	Physical activity and risks of breast and colorectal cancer: a Mendelian randomisation analysis. *Nature Communications*, **2020**, 11, 597	17.4	36
335	Clonal hematopoiesis is associated with risk of severe Covid-19 **2020**,		10
334	Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes. *Nature Genetics*, **2020**, 52, 56-73	36.3	56
333	Cumulative Burden of Colorectal Cancer-Associated Genetic Variants Is More Strongly Associated With Early-Onset vs Late-Onset Cancer. *Gastroenterology*, **2020**, 158, 1274-1286.e12	13.3	47
332	Circulating Levels of Insulin-like Growth Factor 1 and Insulin-like Growth Factor Binding Protein 3 Associate With Risk of Colorectal Cancer Based on Serologic and Mendelian Randomization Analyses. *Gastroenterology*, **2020**, 158, 1300-1312.e20	13.3	45
331	Identification of Novel Loci and New Risk Variant in Known Loci for Colorectal Cancer Risk in East Asians. *Cancer Epidemiology Biomarkers and Prevention*, **2020**, 29, 477-486	4	4
330	Cancer Risks Associated With Germline Pathogenic Variants: An International Study of 524 Families. *Journal of Clinical Oncology*, **2020**, 38, 674-685	2.2	133
329	Effectiveness of the Genomics ADvISER decision aid for the selection of secondary findings from genomic sequencing: a randomized clinical trial. *Genetics in Medicine*, **2020**, 22, 727-735	8.1	12
328	Cancer Susceptibility Mutations in Patients With Urothelial Malignancies. *Journal of Clinical Oncology*, **2020**, 38, 406-414	2.2	31

327	Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of BRCA1 and BRCA2 pathogenic variants. *Genetics in Medicine*, **2020**, 22, 1653-1666	8.1	34
326	A Rare Mutation Predominant in Ashkenazi Jews Confers Risk of Multiple Cancers. *Cancer Research*, **2020**, 80, 3732-3744	10.1	7
325	Genome-wide Modeling of Polygenic Risk Score in Colorectal Cancer Risk. *American Journal of Human Genetics*, **2020**, 107, 432-444	11	31
324	Cancer therapy shapes the fitness landscape of clonal hematopoiesis. *Nature Genetics*, **2020**, 52, 1219-1226	36.3	103
323	Circulating bilirubin levels and risk of colorectal cancer: serological and Mendelian randomization analyses. *BMC Medicine*, **2020**, 18, 229	11.4	11
322	Inherited Rare, Deleterious Variants in ATM Increase Lung Adenocarcinoma Risk. *Journal of Thoracic Oncology*, **2020**, 15, 1871-1879	8.9	4
321	Mutation Rates in Cancer Susceptibility Genes in Patients With Breast Cancer With Multiple Primary Cancers. *JCO Precision Oncology*, **2020**, 4,	3.6	2
320	Adiposity, metabolites, and colorectal cancer risk: Mendelian randomization study. *BMC Medicine*, **2020**, 18, 396	11.4	17
319	Inherited variants at 3q13.33 and 3p24.1 are associated with risk of diffuse large B-cell lymphoma and implicate immune pathways. *Human Molecular Genetics*, **2020**, 29, 70-79	5.6	12
318	Genetic Factors: Hereditary Cancer Predisposition Syndromes **2020**, 180-208.e11		2
317	Fumarate hydratase FH c.1431_1433dupAAA (p.Lys477dup) variant is not associated with cancer including renal cell carcinoma. *Human Mutation*, **2020**, 41, 103-109	4.7	11
316	Two truncating variants in FANCC and breast cancer risk. *Scientific Reports*, **2019**, 9, 12524	4.9	2
315	Shared heritability and functional enrichment across six solid cancers. *Nature Communications*, **2019** , 10, 431	17.4	45
314	Mendelian randomisation study of height and body mass index as modifiers of ovarian cancer risk in 22,588 BRCA1 and BRCA2 mutation carriers. *British Journal of Cancer*, **2019**, 121, 180-192	8.7	13
313	BRCA1 and BRCA2 pathogenic sequence variants in women of African origin or ancestry. *Human Mutation*, **2019**, 40, 1781-1796	4.7	16
312	Genome-wide association and transcriptome studies identify target genes and risk loci for breast cancer. *Nature Communications*, **2019**, 10, 1741	17.4	47
311	CHEK2 Alleles Predispose to Renal Cancer in Poland-In Reply. *JAMA Oncology*, **2019**, 5, 576-577	13.4	
310	Microsatellite Instability Is Associated With the Presence of Lynch Syndrome Pan-Cancer. *Journal of Clinical Oncology*, **2019**, 37, 286-295	2.2	203

309	Genetically Determined Height and Risk of Non-hodgkin Lymphoma. *Frontiers in Oncology*, **2019**, 9, 1539	5.3	1
308	Novel Common Genetic Susceptibility Loci for Colorectal Cancer. *Journal of the National Cancer Institute*, **2019**, 111, 146-157	9.7	67
307	Genetic overlap between autoimmune diseases and non-Hodgkin lymphoma subtypes. *Genetic Epidemiology*, **2019**, 43, 844-863	2.6	15
306	Familial Kidney Cancer: Implications of New Syndromes and Molecular Insights. *European Urology*, **2019**, 76, 754-764	10.2	42
305	Tumour lineage shapes BRCA-mediated phenotypes. *Nature*, **2019**, 571, 576-579	50.4	170
304	Pathogenic Loss-of-Function Germline Mutations in Patients With Solid Tumors. *JCO Precision Oncology*, **2019**, 3,	3.6	1
303	The :p.Arg658* truncating variant is associated with risk of triple-negative breast cancer. *Npj Breast Cancer*, **2019**, 5, 38	7.8	12
302	Genetic variant predictors of gene expression provide new insight into risk of colorectal cancer. *Human Genetics*, **2019**, 138, 307-326	6.3	17
301	Toward automation of germline variant curation in clinical cancer genetics. *Genetics in Medicine*, **2019**, 21, 2116-2125	8.1	14
300	Health outcomes, utility and costs of returning incidental results from genomic sequencing in a Canadian cancer population: protocol for a mixed-methods randomised controlled trial. *BMJ Open*, **2019**, 9, e031092	3	5
299	Understanding inherited risk in unselected newly diagnosed patients with endometrial cancer. *JCO Precision Oncology*, **2019**, 3,	3.6	2
298	Outcome of Pancreatic Cancer Surveillance Among High-Risk Individuals Tested for Germline Mutations in and. *Cancer Prevention Research*, **2019**, 12, 599-608	3.2	4
297	Germline deletion of in familial acute lymphoblastic leukemia. *Blood Advances*, **2019**, 3, 1039-1046	7.8	13
296	A case for expert curation: an overview of cancer curation in the Clinical Genome Resource (ClinGen). *Journal of Physical Education and Sports Management*, **2019**, 5,	2.8	7
295	Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes. *American Journal of Human Genetics*, **2019**, 104, 21-34	11	363
294	Height and Body Mass Index as Modifiers of Breast Cancer Risk in BRCA1/2 Mutation Carriers: A Mendelian Randomization Study. *Journal of the National Cancer Institute*, **2019**, 111, 350-364	9.7	22
293	Determining the clinical validity of hereditary colorectal cancer and polyposis susceptibility genes using the Clinical Genome Resource Clinical Validity Framework. *Genetics in Medicine*, **2019**, 21, 1507-1516	8.1	11
292	Clinical validity assessment of genes frequently tested on hereditary breast and ovarian cancer susceptibility sequencing panels. *Genetics in Medicine*, **2019**, 21, 1497-1506	8.1	32

291	Discovery of common and rare genetic risk variants for colorectal cancer. *Nature Genetics*, **2019**, 51, 76-87	36.3	177
290	A counseling framework for moderate-penetrance colorectal cancer susceptibility genes. *Genetics in Medicine*, **2018**, 20, 1324-1327	8.1	20
289	Prospective Evaluation of Germline Alterations in Patients With Exocrine Pancreatic Neoplasms. *Journal of the National Cancer Institute*, **2018**, 110, 1067-1074	9.7	103
288	Mutational spectrum in a worldwide study of 29,700 families with BRCA1 or BRCA2 mutations. *Human Mutation*, **2018**, 39, 593-620	4.7	138
287	The Genomics ADvISER: development and usability testing of a decision aid for the selection of incidental sequencing results. *European Journal of Human Genetics*, **2018**, 26, 984-995	5.3	25
286	High-depth whole genome sequencing of an Ashkenazi Jewish reference panel: enhancing sensitivity, accuracy, and imputation. *Human Genetics*, **2018**, 137, 343-355	6.3	16
285	Evaluation of a decision aid for incidental genomic results, the Genomics ADvISER: protocol for a mixed methods randomised controlled trial. *BMJ Open*, **2018**, 8, e021876	3	18
284	Germline Lysine-Specific Demethylase 1 () Mutations Confer Susceptibility to Multiple Myeloma. *Cancer Research*, **2018**, 78, 2747-2759	10.1	32
283	A Transcriptome-Wide Association Study Among 97,898 Women to Identify Candidate Susceptibility Genes for Epithelial Ovarian Cancer Risk. *Cancer Research*, **2018**, 78, 5419-5430	10.1	32
282	HLA Class I and II Diversity Contributes to the Etiologic Heterogeneity of Non-Hodgkin Lymphoma Subtypes. *Cancer Research*, **2018**, 78, 4086-4096	10.1	18
281	Germline mutations in children and adults with cancer. *Journal of Physical Education and Sports Management*, **2018**, 4,	2.8	20
280	Frequency of actionable cancer predisposing germline mutations in patients with lung cancers.. *Journal of Clinical Oncology*, **2018**, 36, 1504-1504	2.2	2
279	Novel pedigree analysis implicates DNA repair and chromatin remodeling in multiple myeloma risk. *PLoS Genetics*, **2018**, 14, e1007111	6	20
278	BRCA Challenge: BRCA Exchange as a global resource for variants in BRCA1 and BRCA2. *PLoS Genetics*, **2018**, 14, e1007752	6	90
277	Two high-risk susceptibility loci at 6p25.3 and 14q32.13 for Waldenstrm macroglobulinemia. *Nature Communications*, **2018**, 9, 4182	17.4	8
276	Integrating somatic variant data and biomarkers for germline variant classification in cancer predisposition genes. *Human Mutation*, **2018**, 39, 1542-1552	4.7	23
275	Prevalence of Germline Mutations in Cancer Susceptibility Genes in Patients With Advanced Renal Cell Carcinoma. *JAMA Oncology*, **2018**, 4, 1228-1235	13.4	66
274	Evaluation of copy-number variants as modifiers of breast and ovarian cancer risk for BRCA1 pathogenic variant carriers. *European Journal of Human Genetics*, **2017**, 25, 432-438	5.3	15

273	Psychosocial factors associated with the uptake of contralateral prophylactic mastectomy among BRCA1/2 mutation noncarriers with newly diagnosed breast cancer. *Breast Cancer Research and Treatment*, **2017**, 162, 297-306	4.4	12
272	Utility of prospective pathologic evaluation to inform clinical genetic testing for hereditary leiomyomatosis and renal cell carcinoma. *Cancer*, **2017**, 123, 2452-2458	6.4	9
271	Genome-wide association analysis implicates dysregulation of immunity genes in chronic lymphocytic leukaemia. *Nature Communications*, **2017**, 8, 14175	17.4	54
270	NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast and Ovarian, Version 2.2017. *Journal of the National Comprehensive Cancer Network: JNCCN*, **2017**, 15, 9-20	7.3	319
269	The contribution of pathogenic variants in breast cancer susceptibility genes to familial breast cancer risk. *Npj Breast Cancer*, **2017**, 3, 22	7.8	78
268	Multigene Testing for Hereditary Cancer: When, Why, and How. *Journal of the National Comprehensive Cancer Network: JNCCN*, **2017**, 15, 741-743	7.3	5
267	Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. *Nature Genetics*, **2017**, 49, 680-691	36.3	190
266	Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer. *Nature Genetics*, **2017**, 49, 1767-1778	36.3	186
265	Interest and Attitudes of Patients With Advanced Cancer With Regard to Secondary Germline Findings From Tumor Genomic Profiling. *Journal of Oncology Practice*, **2017**, 13, e590-e601	3.1	19
264	Prospective Genomic Profiling of Prostate Cancer Across Disease States Reveals Germline and Somatic Alterations That May Affect Clinical Decision Making. *JCO Precision Oncology*, **2017**, 2017,	3.6	151
263	Reply to R.L. Nussbaum et al and J.S. Dolinsky et al. *Journal of Clinical Oncology*, **2017**, 35, 1262-1263	2.2	1
262	Prediction of Breast and Prostate Cancer Risks in Male BRCA1 and BRCA2 Mutation Carriers Using Polygenic Risk Scores. *Journal of Clinical Oncology*, **2017**, 35, 2240-2250	2.2	101
261	Mutation Detection in Patients With Advanced Cancer by Universal Sequencing of Cancer-Related Genes in Tumor and Normal DNA vs Guideline-Based Germline Testing. *JAMA - Journal of the American Medical Association*, **2017**, 318, 825-835	27.4	235
260	Integrative clinical genomics of metastatic cancer. *Nature*, **2017**, 548, 297-303	50.4	440
259	Counseling and Testing for Inherited Predisposition to Cancer **2017**, 45-57		
258	Lupus-related single nucleotide polymorphisms and risk of diffuse large B-cell lymphoma. *Lupus Science and Medicine*, **2017**, 4, e000187	4.6	10
257	Germline mutations detected in pediatric sequencing studies impact parents' evaluation and care. *Journal of Physical Education and Sports Management*, **2017**, 3,	2.8	13
256	Comprehensive detection of germline variants by MSK-IMPACT, a clinical diagnostic platform for solid tumor molecular oncology and concurrent cancer predisposition testing. *BMC Medical Genomics*, **2017**, 10, 33	3.7	64

255	Association of breast cancer risk in BRCA1 and BRCA2 mutation carriers with genetic variants showing differential allelic expression: identification of a modifier of breast cancer risk at locus 11q22.3. *Breast Cancer Research and Treatment*, **2017**, 161, 117-134	4.4	15
254	The OncoArray Consortium: A Network for Understanding the Genetic Architecture of Common Cancers. *Cancer Epidemiology Biomarkers and Prevention*, **2017**, 26, 126-135	4	183
253	Evaluation of Polygenic Risk Scores for Breast and Ovarian Cancer Risk Prediction in BRCA1 and BRCA2 Mutation Carriers. *Journal of the National Cancer Institute*, **2017**, 109,	9.7	153
252	Decision-Making Preferences About Secondary Germline Findings That Arise From Tumor Genomic Profiling Among Patients With Advanced Cancers. *JCO Precision Oncology*, **2017**, 1,	3.6	4
251	No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer. *Gynecologic Oncology*, **2016**, 141, 386-401	4.9	15
250	Genome Sequencing of Multiple Primary Tumors Reveals a Novel PALB2 Variant. *Journal of Clinical Oncology*, **2016**, 34, e61-7	2.2	6
249	Inheritance of deleterious mutations at both BRCA1 and BRCA2 in an international sample of 32,295 women. *Breast Cancer Research*, **2016**, 18, 112	8.3	25
248	The future of clinical cancer genomics. *Seminars in Oncology*, **2016**, 43, 615-622	5.5	18
247	Identification of four novel susceptibility loci for oestrogen receptor negative breast cancer. *Nature Communications*, **2016**, 7, 11375	17.4	64
246	Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast-ovarian cancer susceptibility locus. *Nature Communications*, **2016**, 7, 12675	17.4	53
245	Characterization of a novel germline PALB2 duplication in a hereditary breast and ovarian cancer family. *Breast Cancer Research and Treatment*, **2016**, 160, 447-456	4.4	12
244	Meta-analysis of genome-wide association studies discovers multiple loci for chronic lymphocytic leukemia. *Nature Communications*, **2016**, 7, 10933	17.4	70
243	Age- and Tumor Subtype-Specific Breast Cancer Risk Estimates for CHEK2*1100delC Carriers. *Journal of Clinical Oncology*, **2016**, 34, 2750-60	2.2	107
242	Counselling framework for moderate-penetrance cancer-susceptibility mutations. *Nature Reviews Clinical Oncology*, **2016**, 13, 581-8	19.4	200
241	Germline Variants in Targeted Tumor Sequencing Using Matched Normal DNA. *JAMA Oncology*, **2016**, 2, 104-11	13.4	198
240	Treatment of infertility does not increase the risk of ovarian cancer among women with a BRCA1 or BRCA2 mutation. *Fertility and Sterility*, **2016**, 105, 781-785	4.8	28
239	Genetically predicted longer telomere length is associated with increased risk of B-cell lymphoma subtypes. *Human Molecular Genetics*, **2016**, 25, 1663-76	5.6	39
238	Genomic Biomarkers for Breast Cancer Risk. *Advances in Experimental Medicine and Biology*, **2016**, 882, 1-32	3.6	26

237	Breast cancer risk variants at 6q25 display different phenotype associations and regulate ESR1, RMND1 and CCDC170. *Nature Genetics*, **2016**, 48, 374-86	36.3	93
236	Outcome of genetic evaluation of patients with kidney cancer referred for suspected hereditary cancer syndromes. *Urologic Oncology: Seminars and Original Investigations*, **2016**, 34, 238.e1-7	2.8	11
235	BRCA2 Polymorphic Stop Codon K3326X and the Risk of Breast, Prostate, and Ovarian Cancers. *Journal of the National Cancer Institute*, **2016**, 108,	9.7	65
234	Collaborative science in the next-generation sequencing era: a viewpoint on how to combine exome sequencing data across sites to identify novel disease susceptibility genes. *Briefings in Bioinformatics*, **2016**, 17, 672-7	13.4	5
233	Prospective registry of multiplex testing (PROMPT): A web-based platform to assess cancer risk of genetic variants.. *Journal of Clinical Oncology*, **2016**, 34, 1518-1518	2.2	1
232	Fine-Scale Mapping at 9p22.2 Identifies Candidate Causal Variants That Modify Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. *PLoS ONE*, **2016**, 11, e0158801	3.7	7
231	Uterine Cancer After Risk-Reducing Salpingo-oophorectomy Without Hysterectomy in Women With BRCA Mutations. *JAMA Oncology*, **2016**, 2, 1434-1440	13.4	151
230	Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer. *New England Journal of Medicine*, **2016**, 375, 443-53	59.2	791
229	Twenty-one-gene recurrence score assay in BRCA-associated versus sporadic breast cancers: Differences based on germline mutation status. *Cancer*, **2016**, 122, 1178-84	6.4	29
228	Genetic/Familial High-Risk Assessment: Breast and Ovarian, Version 2.2015. *Journal of the National Comprehensive Cancer Network: JNCCN*, **2016**, 14, 153-62	7.3	123
227	Identification of independent association signals and putative functional variants for breast cancer risk through fine-scale mapping of the 12p11 locus. *Breast Cancer Research*, **2016**, 18, 64	8.3	25
226	Reliable Detection of Mismatch Repair Deficiency in Colorectal Cancers Using Mutational Load in Next-Generation Sequencing Panels. *Journal of Clinical Oncology*, **2016**, 34, 2141-7	2.2	170
225	Evaluation of ACMG-Guideline-Based Variant Classification of Cancer Susceptibility and Non-Cancer-Associated Genes in Families Affected by Breast Cancer. *American Journal of Human Genetics*, **2016**, 98, 801-817	11	86
224	Male breast cancer in BRCA1 and BRCA2 mutation carriers: pathology data from the Consortium of Investigators of Modifiers of BRCA1/2. *Breast Cancer Research*, **2016**, 18, 15	8.3	58
223	Conflicting Interpretation of Genetic Variants and Cancer Risk by Commercial Laboratories as Assessed by the Prospective Registry of Multiplex Testing. *Journal of Clinical Oncology*, **2016**, 34, 4071-4078	2.2	110
222	A Recurrent ERCC3 Truncating Mutation Confers Moderate Risk for Breast Cancer. *Cancer Discovery* , **2016**, 6, 1267-1275	24.4	30
221	Identification of six new susceptibility loci for invasive epithelial ovarian cancer. *Nature Genetics*, **2015**, 47, 164-71	36.3	177
220	FANCM c.5791C>T nonsense mutation (rs144567652) induces exon skipping, affects DNA repair activity and is a familial breast cancer risk factor. *Human Molecular Genetics*, **2015**, 24, 5345-55	5.6	68

219	Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer. *JAMA - Journal of the American Medical Association*, **2015**, 313, 1347-61	27.4	286
218	Candidate genetic modifiers for breast and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers. *Cancer Epidemiology Biomarkers and Prevention*, **2015**, 24, 308-16	4	20
217	An original phylogenetic approach identified mitochondrial haplogroup T1a1 as inversely associated with breast cancer risk in BRCA2 mutation carriers. *Breast Cancer Research*, **2015**, 17, 61	8.3	16
216	Analysis of Heritability and Shared Heritability Based on Genome-Wide Association Studies for Thirteen Cancer Types. *Journal of the National Cancer Institute*, **2015**, 107, djv279	9.7	107
215	Identification of germline genetic mutations in patients with pancreatic cancer. *Cancer*, **2015**, 121, 4382-8	6.4	117
214	Assessing associations between the AURKA-HMMR-TPX2-TUBG1 functional module and breast cancer risk in BRCA1/2 mutation carriers. *PLoS ONE*, **2015**, 10, e0120020	3.7	26
213	Germline ETV6 Mutations Confer Susceptibility to Acute Lymphoblastic Leukemia and Thrombocytopenia. *PLoS Genetics*, **2015**, 11, e1005262	6	99
212	A genome-wide association study of marginal zone lymphoma shows association to the HLA region. *Nature Communications*, **2015**, 6, 5751	17.4	44
211	Prediction of breast cancer risk based on profiling with common genetic variants. *Journal of the National Cancer Institute*, **2015**, 107,	9.7	324
210	Cell-type-specific enrichment of risk-associated regulatory elements at ovarian cancer susceptibility loci. *Human Molecular Genetics*, **2015**, 24, 3595-607	5.6	32
209	Tissue-Specific Enrichment of Lymphoma Risk Loci in Regulatory Elements. *PLoS ONE*, **2015**, 10, e0139360	3.7	5
208	Two decades after BRCA: setting paradigms in personalized cancer care and prevention. *Science*, **2014**, 343, 1466-70	33.3	233
207	Genome-wide association study identifies multiple susceptibility loci for diffuse large B cell lymphoma. *Nature Genetics*, **2014**, 46, 1233-8	36.3	108
206	Genome-wide association study identifies five susceptibility loci for follicular lymphoma outside the HLA region. *American Journal of Human Genetics*, **2014**, 95, 462-71	11	74
205	Cancer genomics and inherited risk. *Journal of Clinical Oncology*, **2014**, 32, 687-98	2.2	100
204	Sequencing an Ashkenazi reference panel supports population-targeted personal genomics and illuminates Jewish and European origins. *Nature Communications*, **2014**, 5, 4835	17.4	115
203	Assessment of individuals with BRCA1 and BRCA2 large rearrangements in high-risk breast and ovarian cancer families. *Breast Cancer Research and Treatment*, **2014**, 145, 625-34	4.4	7
202	Genetic/familial high-risk assessment: breast and ovarian, version 1.2014. *Journal of the National Comprehensive Cancer Network: JNCCN*, **2014**, 12, 1326-38	7.3	101

201	Genome-wide analysis of the role of copy-number variation in pancreatic cancer risk. *Frontiers in Genetics*, **2014**, 5, 29	4.5	10
200	Clinical features and management of BRCA1 and BRCA2-associated prostate cancer. *Frontiers in Bioscience - Elite*, **2014**, 6, 15-30	1.6	18
199	DNA glycosylases involved in base excision repair may be associated with cancer risk in BRCA1 and BRCA2 mutation carriers. *PLoS Genetics*, **2014**, 10, e1004256	6	33
198	Associations of common breast cancer susceptibility alleles with risk of breast cancer subtypes in BRCA1 and BRCA2 mutation carriers. *Breast Cancer Research*, **2014**, 16, 3416	8.3	46
197	Genetic variation in DNA repair pathways and risk of non-Hodgkin's lymphoma. *PLoS ONE*, **2014**, 9, e101685	3.7	12
196	Genetic Factors **2014**, 169-187.e7		1
195	COMPLEXO: identifying the missing heritability of breast cancer via next generation collaboration. *Breast Cancer Research*, **2013**, 15, 402	8.3	30
194	Revealing the incidentalome when targeting the tumor genome. *JAMA - Journal of the American Medical Association*, **2013**, 310, 795-6	27.4	51
193	A recurrent germline PAX5 mutation confers susceptibility to pre-B cell acute lymphoblastic leukemia. *Nature Genetics*, **2013**, 45, 1226-1231	36.3	205
192	Description and pilot results from a novel method for evaluating return of incidental findings from next-generation sequencing technologies. *Genetics in Medicine*, **2013**, 15, 721-8	8.1	35
191	Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. *Nature Genetics*, **2013**, 45, 371-84, 384e1-2	36.3	422
190	Genome-wide association study identifies multiple risk loci for chronic lymphocytic leukemia. *Nature Genetics*, **2013**, 45, 868-76	36.3	147
189	Should all BRCA1 mutation carriers with stage I breast cancer receive chemotherapy?. *Breast Cancer Research and Treatment*, **2013**, 138, 273-9	4.4	25
188	Identification of a BRCA2-specific modifier locus at 6p24 related to breast cancer risk. *PLoS Genetics*, **2013**, 9, e1003173	6	90
187	Genome-wide association study in BRCA1 mutation carriers identifies novel loci associated with breast and ovarian cancer risk. *PLoS Genetics*, **2013**, 9, e1003212	6	209
186	Susceptibility loci associated with specific and shared subtypes of lymphoid malignancies. *PLoS Genetics*, **2013**, 9, e1003220	6	38
185	Evidence of gene-environment interactions between common breast cancer susceptibility loci and established environmental risk factors. *PLoS Genetics*, **2013**, 9, e1003284	6	112
184	Multiplex genetic testing for cancer susceptibility: out on the high wire without a net?. *Journal of Clinical Oncology*, **2013**, 31, 1267-70	2.2	184

183	Risk of metachronous breast cancer after BRCA mutation-associated ovarian cancer. *Cancer*, **2013**, 119, 1344-8	6.4	37
182	Gene patents and personalized cancer care: impact of the Myriad case on clinical oncology. *Journal of Clinical Oncology*, **2013**, 31, 2743-8	2.2	46
181	Translating genomics in cancer care. *Journal of the National Comprehensive Cancer Network: JNCCN*, **2013**, 11, 1343-53	7.3	53
180	Assessment of SLX4 Mutations in Hereditary Breast Cancers. *PLoS ONE*, **2013**, 8, e66961	3.7	24
179	Systematic immunohistochemistry screening for Lynch syndrome in early age-of-onset colorectal cancer patients undergoing surgical resection. *Journal of the American College of Surgeons*, **2012**, 214, 61-7	4.4	29
178	Germline BRCA mutation does not prevent response to taxane-based therapy for the treatment of castration-resistant prostate cancer. *BJU International*, **2012**, 109, 713-9	5.6	31
177	Common variants at 12p11, 12q24, 9p21, 9q31.2 and in ZNF365 are associated with breast cancer risk for BRCA1 and/or BRCA2 mutation carriers. *Breast Cancer Research*, **2012**, 14, R33	8.3	70
176	Prevalence of BRCA1 and BRCA2 mutations in Ashkenazi Jewish families with breast and pancreatic cancer. *Cancer*, **2012**, 118, 493-9	6.4	71
175	Ovarian cancer susceptibility alleles and risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers. *Human Mutation*, **2012**, 33, 690-702	4.7	31
174	Evaluation of chromosome 6p22 as a breast cancer risk modifier locus in a follow-up study of BRCA2 mutation carriers. *Breast Cancer Research and Treatment*, **2012**, 136, 295-302	4.4	3
173	Rare variants in XRCC2 as breast cancer susceptibility alleles. *Journal of Medical Genetics*, **2012**, 49, 618-20	5.8	37
172	Rare de novo germline copy-number variation in testicular cancer. *American Journal of Human Genetics*, **2012**, 91, 379-83	11	20
171	Breast cancer risk and 6q22.33: combined results from Breast Cancer Association Consortium and Consortium of Investigators on Modifiers of BRCA1/2. *PLoS ONE*, **2012**, 7, e35706	3.7	10
170	Improved survival for BRCA2-associated serous ovarian cancer compared with both BRCA-negative and BRCA1-associated serous ovarian cancer. *Cancer*, **2012**, 118, 3703-9	6.4	61
169	Incorporating information regarding preimplantation genetic diagnosis into discussions concerning testing and risk management for BRCA1/2 mutations: a qualitative study of patient preferences. *Cancer*, **2012**, 118, 6270-7	6.4	20
168	Y chromosome haplogroups and prostate cancer in populations of European and Ashkenazi Jewish ancestry. *Human Genetics*, **2012**, 131, 1173-85	6.3	11
167	The KL-VS sequence variant of Klotho and cancer risk in BRCA1 and BRCA2 mutation carriers. *Breast Cancer Research and Treatment*, **2012**, 132, 1119-26	4.4	7
166	Risks to relatives in genomic research: a duty to warn?. *American Journal of Bioethics*, **2012**, 12, 12-4	1.1	17

165	A nonsynonymous polymorphism in IRS1 modifies risk of developing breast and ovarian cancers in BRCA1 and ovarian cancer in BRCA2 mutation carriers. *Cancer Epidemiology Biomarkers and Prevention*, **2012**, 21, 1362-70	4	20
164	Heterozygous mutations in DNA repair genes and hereditary breast cancer: a question of power. *PLoS Genetics*, **2012**, 8, e1003008	6	13
163	Association of a HOXB13 variant with breast cancer. *New England Journal of Medicine*, **2012**, 367, 480-1	59.2	20
162	Common variants at the 19p13.1 and ZNF365 loci are associated with ER subtypes of breast cancer and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers. *Cancer Epidemiology Biomarkers and Prevention*, **2012**, 21, 645-57	4	44
161	Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). *Cancer Epidemiology Biomarkers and Prevention*, **2012**, 21, 134-47	4	411
160	Comparison of 6q25 breast cancer hits from Asian and European Genome Wide Association Studies in the Breast Cancer Association Consortium (BCAC). *PLoS ONE*, **2012**, 7, e42380	3.7	49
159	Germline mutations in BAP1 predispose to melanocytic tumors. *Nature Genetics*, **2011**, 43, 1018-21	36.3	562
158	Germline PALB2 mutation analysis in breast-pancreas cancer families. *Journal of Medical Genetics*, **2011**, 48, 523-5	5.8	24
157	Common breast cancer susceptibility alleles are associated with tumour subtypes in BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2. *Breast Cancer Research*, **2011**, 13, R110	8.3	62
156	Polymorphisms of ADIPOQ and ADIPOR1 and prostate cancer risk. *Metabolism: Clinical and Experimental*, **2011**, 60, 1234-43	12.7	44
155	Genetics, genomics, and cancer risk assessment: State of the Art and Future Directions in the Era of Personalized Medicine. *Ca-A Cancer Journal for Clinicians*, **2011**, 61, 327-59	220.7	128
154	BRCA1 R71K missense mutation contributes to cancer predisposition by increasing alternative transcript levels. *Breast Cancer Research and Treatment*, **2011**, 130, 1051-6	4.4	12
153	Haplotype structure in Ashkenazi Jewish BRCA1 and BRCA2 mutation carriers. *Human Genetics*, **2011**, 130, 685-99	6.3	15
152	Personalized medicine: new genomics, old lessons. *Human Genetics*, **2011**, 130, 3-14	6.3	146
151	Common alleles at 6q25.1 and 1p11.2 are associated with breast cancer risk for BRCA1 and BRCA2 mutation carriers. *Human Molecular Genetics*, **2011**, 20, 3304-21	5.6	62
150	Including additional controls from public databases improves the power of a genome-wide association study. *Human Heredity*, **2011**, 72, 21-34	1.1	11
149	Genetic variation at 9p22.2 and ovarian cancer risk for BRCA1 and BRCA2 mutation carriers. *Journal of the National Cancer Institute*, **2011**, 103, 105-16	9.7	37
148	Interplay between BRCA1 and RHAMM regulates epithelial apicobasal polarization and may influence risk of breast cancer. *PLoS Biology*, **2011**, 9, e1001199	9.7	73

147	A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor-negative breast cancer in the general population. *Nature Genetics*, **2010**, 42, 885-92	36.3	276
146	American Society of Clinical Oncology policy statement update: genetic and genomic testing for cancer susceptibility. *Journal of Clinical Oncology*, **2010**, 28, 893-901	2.2	349
145	Common breast cancer susceptibility alleles and the risk of breast cancer for BRCA1 and BRCA2 mutation carriers: implications for risk prediction. *Cancer Research*, **2010**, 70, 9742-54	10.1	147
144	Blood biomarker levels to aid discovery of cancer-related single-nucleotide polymorphisms: kallikreins and prostate cancer. *Cancer Prevention Research*, **2010**, 3, 611-9	3.2	50
143	New pharmacogenomic paradigm in breast cancer treatment. *Journal of Clinical Oncology*, **2010**, 28, 4665-6	2.2	13
142	Germline BRCA mutations denote a clinicopathologic subset of prostate cancer. *Clinical Cancer Research*, **2010**, 16, 2115-21	12.9	196
141	Common genetic variants and modification of penetrance of BRCA2-associated breast cancer. *PLoS Genetics*, **2010**, 6, e1001183	6	74
140	Susceptibility loci associated with prostate cancer progression and mortality. *Clinical Cancer Research*, **2010**, 16, 2819-32	12.9	64
139	Diagnosing hereditary colorectal cancer. *Clinical Colorectal Cancer*, **2010**, 9, 205-11	3.8	12
138	Genome-wide association studies of cancer predisposition. *Hematology/Oncology Clinics of North America*, **2010**, 24, 973-96	3.1	33
137	Genome-wide association studies of cancer. *Journal of Clinical Oncology*, **2010**, 28, 4255-67	2.2	127
136	Ethicolegal aspects of cancer genetics. *Cancer Treatment and Research*, **2010**, 155, 1-14	3.5	8
135	Inherited predisposition to cancer: introduction and overview. *Hematology/Oncology Clinics of North America*, **2010**, 24, 793-7	3.1	5
134	Genetic/familial high-risk assessment: breast and ovarian. *Journal of the National Comprehensive Cancer Network: JNCCN*, **2010**, 8, 562-94	7.3	169
133	Absence of genomic BRCA1 and BRCA2 rearrangements in Ashkenazi breast and ovarian cancer families. *Breast Cancer Research and Treatment*, **2010**, 123, 581-5	4.4	15
132	Altered tumor formation and evolutionary selection of genetic variants in the human MDM4 oncogene. *Proceedings of the National Academy of Sciences of the United States of America*, **2009**, 106, 10236-41	11.5	56
131	The 6q22.33 locus and breast cancer susceptibility. *Cancer Epidemiology Biomarkers and Prevention*, **2009**, 18, 2468-75	4	22
130	BRCA germline mutations in Jewish patients with pancreatic adenocarcinoma. *Journal of Clinical Oncology*, **2009**, 27, 433-8	2.2	160

129	Common variants in LSP1, 2q35 and 8q24 and breast cancer risk for BRCA1 and BRCA2 mutation carriers. *Human Molecular Genetics*, **2009**, 18, 4442-56	5.6	91
128	Mutations in a gene encoding a midbody kelch protein in familial and sporadic classical Hodgkin lymphoma lead to binucleated cells. *Proceedings of the National Academy of Sciences of the United States of America*, **2009**, 106, 14920-5	11.5	46
127	cDNA analysis demonstrates that the BRCA2 intronic variant IVS4-12del5 is a deleterious mutation. *Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis*, **2009**, 663, 84-9	3.3	8
126	A germline JAK2 SNP is associated with predisposition to the development of JAK2(V617F)-positive myeloproliferative neoplasms. *Nature Genetics*, **2009**, 41, 455-9	36.3	287
125	The Scientific Foundation for personal genomics: recommendations from a National Institutes of Health-Centers for Disease Control and Prevention multidisciplinary workshop. *Genetics in Medicine* , **2009**, 11, 559-67	8.1	186
124	A rapid and reliable test for BRCA1 and BRCA2 founder mutation analysis in paraffin tissue using pyrosequencing. *Journal of Molecular Diagnostics*, **2009**, 11, 176-81	5.1	16
123	Immunohistochemistry as first-line screening for detecting colorectal cancer patients at risk for hereditary nonpolyposis colorectal cancer syndrome: a 2-antibody panel may be as predictive as a 4-antibody panel. *American Journal of Surgical Pathology*, **2009**, 33, 1639-45	6.7	128
122	Identification and characterization of novel SNPs in CHEK2 in Ashkenazi Jewish men with prostate cancer. *Cancer Letters*, **2008**, 270, 173-80	9.9	15
121	Genome-wide association study provides evidence for a breast cancer risk locus at 6q22.33. *Proceedings of the National Academy of Sciences of the United States of America*, **2008**, 105, 4340-5	11.5	256
120	Variants of the adiponectin (ADIPOQ) and adiponectin receptor 1 (ADIPOR1) genes and colorectal cancer risk. *JAMA - Journal of the American Medical Association*, **2008**, 300, 1523-31	27.4	113
119	Genomic profiles for disease risk: predictive or premature?. *JAMA - Journal of the American Medical Association*, **2008**, 299, 1353-5	27.4	88
118	Ethical and legal implications of cancer genetic testing: do physicians have a duty to warn patients' relatives about possible genetic risks?. *Journal of Oncology Practice*, **2008**, 4, 229-30	3.1	16
117	Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study. *Journal of Clinical Oncology*, **2008**, 26, 1331-7	2.2	465
116	The signatures of autozygosity among patients with colorectal cancer. *Cancer Research*, **2008**, 68, 2610-21	10.1	42
115	Variants of the adiponectin and adiponectin receptor 1 genes and breast cancer risk. *Cancer Research*, **2008**, 68, 3178-84	10.1	90
114	Analysis of genetic variation in Ashkenazi Jews by high density SNP genotyping. *BMC Genetics*, **2008** , 9, 14	2.6	30
113	Genetic variants in germline TP53 and MDM2 SNP309 are not associated with early onset colorectal cancer. *Journal of Surgical Oncology*, **2008**, 97, 621-5	2.8	8
112	Genetic Factors: Hereditary Cancer Predisposition Syndromes **2008**, 171-191		1

111	Clinical practice. Management of an inherited predisposition to breast cancer. *New England Journal of Medicine*, **2007**, 357, 154-62	59.2	194
110	The BRCA1 Ashkenazi founder mutations occur on common haplotypes and are not highly correlated with anonymous single nucleotide polymorphisms likely to be used in genome-wide case-control association studies. *BMC Genetics*, **2007**, 8, 68	2.6	7
109	Network modeling links breast cancer susceptibility and centrosome dysfunction. *Nature Genetics*, **2007**, 39, 1338-49	36.3	516
108	Ethical and legal aspects of cancer genetic testing. *Seminars in Oncology*, **2007**, 34, 435-43	5.5	25
107	Heterogenic loss of the wild-type BRCA allele in human breast tumorigenesis. *Annals of Surgical Oncology*, **2007**, 14, 2510-8	3.1	72
106	Age at first birth and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. *Breast Cancer Research and Treatment*, **2007**, 105, 221-8	4.4	38
105	AURKA F31I polymorphism and breast cancer risk in BRCA1 and BRCA2 mutation carriers: a consortium of investigators of modifiers of BRCA1/2 study. *Cancer Epidemiology Biomarkers and Prevention*, **2007**, 16, 1416-21	4	26
104	BRCA mutations in women with ductal carcinoma in situ. *Clinical Cancer Research*, **2007**, 13, 4306-10	12.9	26
103	Modeling genetic risk of breast cancer. *JAMA - Journal of the American Medical Association*, **2007**, 297, 2637-9	27.4	7
102	Single-amplicon MSH2 A636P mutation testing in Ashkenazi Jewish patients with colorectal cancer: role in presurgical management. *Annals of Surgery*, **2007**, 245, 560-5	7.8	8
101	RAD51 135G-->C modifies breast cancer risk among BRCA2 mutation carriers: results from a combined analysis of 19 studies. *American Journal of Human Genetics*, **2007**, 81, 1186-200	11	204
100	Reproductive risk factors for ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case-control study. *Lancet Oncology, The*, **2007**, 8, 26-34	21.7	186
99	Localization of breast cancer susceptibility loci by genome-wide SNP linkage disequilibrium mapping. *Genetic Epidemiology*, **2006**, 30, 48-61	2.6	16
98	Tamoxifen and contralateral breast cancer in BRCA1 and BRCA2 carriers: an update. *International Journal of Cancer*, **2006**, 118, 2281-4	7.5	220
97	Prediction of germline mutations and cancer risk in the Lynch syndrome. *JAMA - Journal of the American Medical Association*, **2006**, 296, 1479-87	27.4	271
96	Reducing the risk of gynecologic cancer in the Lynch syndrome. *New England Journal of Medicine*, **2006**, 354, 293-5	59.2	27
95	The role of prevention in oncology practice: results from a 2004 survey of American Society of Clinical Oncology members. *Journal of Clinical Oncology*, **2006**, 24, 2948-57	2.2	38
94	Effect of mammography on breast cancer risk in women with mutations in BRCA1 or BRCA2. *Cancer Epidemiology Biomarkers and Prevention*, **2006**, 15, 2311-3	4	51

93	Preimplantation genetic diagnosis for cancer syndromes: a new challenge for preventive medicine. *JAMA - Journal of the American Medical Association*, **2006**, 296, 2727-30	27.4	58
92	ASCO/SSO review of current role of risk-reducing surgery in common hereditary cancer syndromes. *Journal of Clinical Oncology*, **2006**, 24, 4642-60	2.2	182
91	BRCA mutation frequency and penetrance: new data, old debate. *Journal of the National Cancer Institute*, **2006**, 98, 1675-7	9.7	35
90	Spontaneous and therapeutic abortions and the risk of breast cancer among BRCA mutation carriers. *Breast Cancer Research*, **2006**, 8, R15	8.3	40
89	Cancer survivorship--genetic susceptibility and second primary cancers: research strategies and recommendations. *Journal of the National Cancer Institute*, **2006**, 98, 15-25	9.7	233
88	Increased frequency of disease-causing MYH mutations in colon cancer families. *Carcinogenesis*, **2006**, 27, 2243-9	4.6	39
87	Cancer genetic testing and assisted reproduction. *Journal of Clinical Oncology*, **2006**, 24, 4775-82	2.2	93
86	MDM2 SNP309 accelerates tumor formation in a gender-specific and hormone-dependent manner. *Cancer Research*, **2006**, 66, 5104-10	10.1	256
85	ASCO/SSO review of current role of risk-reducing surgery in common hereditary cancer syndromes. *Annals of Surgical Oncology*, **2006**, 13, 1296-321	3.1	39
84	Genetic/familial high-risk assessment: breast and ovarian. *Journal of the National Comprehensive Cancer Network: JNCCN*, **2006**, 4, 156-76	7.3	43
83	Hereditary cancer predisposition syndromes. *Journal of Clinical Oncology*, **2005**, 23, 276-92	2.2	394
82	Value of immunohistochemical detection of DNA mismatch repair proteins in predicting germline mutation in hereditary colorectal neoplasms. *American Journal of Surgical Pathology*, **2005**, 29, 96-104	6.7	121
81	Evaluation of germline PTEN mutations in endometrial cancer patients. *Gynecologic Oncology*, **2005** , 96, 21-4	4.9	32
80	Germline mutations of AXIN2 are not associated with nonsyndromic colorectal cancer. *Human Mutation*, **2005**, 25, 498-500	4.7	11
79	Colorectal cancer risk in individuals with biallelic or monoallelic mutations of MYH. *International Journal of Cancer*, **2005**, 114, 505-7	7.5	52
78	Effect of pregnancy as a risk factor for breast cancer in BRCA1/BRCA2 mutation carriers. *International Journal of Cancer*, **2005**, 117, 988-91	7.5	131
77	Appropriateness of breast-conserving treatment of breast carcinoma in women with germline mutations in BRCA1 or BRCA2: a clinic-based series. *Cancer*, **2005**, 103, 44-51	6.4	123
76	Ovarian carcinoma screening in women at intermediate risk: impact on quality of life and need for invasive follow-up. *Cancer*, **2005**, 104, 314-20	6.4	23

75	The TP53 mutational spectrum and frequency of CHEK2*1100delC in Li-Fraumeni-like kindreds. *Familial Cancer*, **2005**, 4, 177-81	3	28
74	Combined genetic assessment of transforming growth factor-beta signaling pathway variants may predict breast cancer risk. *Cancer Research*, **2005**, 65, 3454-61	10.1	73
73	Risk of ovarian cancer in BRCA1 and BRCA2 mutation-negative hereditary breast cancer families. *Journal of the National Cancer Institute*, **2005**, 97, 1382-4	9.7	70
72	Functional and genomic approaches reveal an ancient CHEK2 allele associated with breast cancer in the Ashkenazi Jewish population. *Human Molecular Genetics*, **2005**, 14, 555-63	5.6	94
71	Prevention and management of hereditary breast cancer. *Journal of Clinical Oncology*, **2005**, 23, 1656-63	2.2	135
70	Breast cancer risk following bilateral oophorectomy in BRCA1 and BRCA2 mutation carriers: an international case-control study. *Journal of Clinical Oncology*, **2005**, 23, 7491-6	2.2	360
69	Frequency of BRCA1 and BRCA2 mutations in unselected Ashkenazi Jewish patients with colorectal cancer. *Journal of the National Cancer Institute*, **2004**, 96, 68-70	9.7	59
68	MSH6 mutations in hereditary nonpolyposis colon cancer: another slice of the pie. *Journal of Clinical Oncology*, **2004**, 22, 4449-51	2.2	12
67	BRCA mutations and risk of prostate cancer in Ashkenazi Jews. *Clinical Cancer Research*, **2004**, 10, 2918-21	11.9	139
66	TGFBR1*6A and cancer: a meta-analysis of 12 case-control studies. *Journal of Clinical Oncology*, **2004**, 22, 756-8	2.2	75
65	Localization of cancer susceptibility genes by genome-wide single-nucleotide polymorphism linkage-disequilibrium mapping. *Cancer Research*, **2004**, 64, 8116-25	10.1	12
64	Breast MRI for women with hereditary cancer risk. *JAMA - Journal of the American Medical Association*, **2004**, 292, 1368-70	27.4	33
63	The "duty to warn" a patient's family members about hereditary disease risks. *JAMA - Journal of the American Medical Association*, **2004**, 292, 1469-73	27.4	190
62	Increased progesterone receptor expression in benign epithelium of BRCA1-related breast cancers. *Cancer Research*, **2004**, 64, 5051-3	10.1	42
61	A636P testing in Ashkenazi Jews. *Familial Cancer*, **2004**, 3, 223-7	3	7
60	Hereditary ovarian cancer in Ashkenazi Jews. *Familial Cancer*, **2004**, 3, 259-64	3	31
59	The genetics of familial lymphomas. *Current Oncology Reports*, **2004**, 6, 380-7	6.3	9
58	No major association between TGFBR1*6A and prostate cancer. *BMC Genetics*, **2004**, 5, 28	2.6	11

57	A combined analysis of outcome following breast cancer: differences in survival based on BRCA1/BRCA2 mutation status and administration of adjuvant treatment. *Breast Cancer Research*, **2004**, 6, R8-R17	8.3	225
56	Fallopian tube and primary peritoneal carcinomas associated with BRCA mutations. *Journal of Clinical Oncology*, **2003**, 21, 4222-7	2.2	169
55	Shared genetic susceptibility to breast cancer, brain tumors, and Fanconi anemia. *Journal of the National Cancer Institute*, **2003**, 95, 1548-51	9.7	160
54	A636P is associated with early-onset colon cancer in Ashkenazi Jews. *Journal of the American College of Surgeons*, **2003**, 196, 222-5	4.4	25
53	Quality of life in women at risk for ovarian cancer who have undergone risk-reducing oophorectomy. *Gynecologic Oncology*, **2003**, 89, 281-7	4.9	111
52	Epithelial lesions in prophylactic mastectomy specimens from women with BRCA mutations. *Cancer* , **2003**, 97, 1601-8	6.4	79
51	MSH6 germline mutations are rare in colorectal cancer families. *International Journal of Cancer*, **2003**, 107, 571-9	7.5	49
50	Differential recruitment of caspase 8 to cFlip confers sensitivity or resistance to Fas-mediated apoptosis in a subset of familial lymphoma patients. *Leukemia Research*, **2003**, 27, 841-51	2.7	14
49	Frequency of CHEK2*1100delC in New York breast cancer cases and controls. *BMC Medical Genetics* , **2003**, 4, 1	2.1	91
48	BRCA1 and BRCA2 germline mutations in lymphoma patients. *Leukemia and Lymphoma*, **2003**, 44, 127-31	1.9	8
47	TGFBR1*6A and cancer risk: a meta-analysis of seven case-control studies. *Journal of Clinical Oncology*, **2003**, 21, 3236-43	2.2	89
46	Outcome of preventive surgery and screening for breast and ovarian cancer in BRCA mutation carriers. *Journal of Clinical Oncology*, **2002**, 20, 1260-8	2.2	363
45	Considerations in genetic counseling for inherited breast cancer predisposition. *Seminars in Radiation Oncology*, **2002**, 12, 362-70	5.5	
44	Similar patterns of genomic alterations characterize primary mediastinal large-B-cell lymphoma and diffuse large-B-cell lymphoma. *Genes Chromosomes and Cancer*, **2002**, 33, 114-22	5	58
43	BLM heterozygosity and the risk of colorectal cancer. *Science*, **2002**, 297, 2013	33.3	144
42	Estrogen receptor-beta expression in hereditary breast cancer. *Journal of Clinical Oncology*, **2002**, 20, 3752-3; author reply 3753	2.2	18
41	Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. *Journal of the National Cancer Institute*, **2002**, 94, 1773-9	9.7	266
40	Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. *New England Journal of Medicine*, **2002**, 346, 1609-15	59.2	1198

39	Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations. *Clinical Cancer Research*, **2002**, 8, 3776-81	12.9	101
38	Rare variants of ATM and risk for Hodgkin's disease and radiation-associated breast cancers. *Clinical Cancer Research*, **2002**, 8, 3813-9	12.9	28
37	Psychosocial predictors of BRCA counseling and testing decisions among urban African-American women. *Cancer Epidemiology Biomarkers and Prevention*, **2002**, 11, 1579-85	4	72
36	Insurance reimbursement for risk-reducing mastectomy and oophorectomy in women with BRCA1 or BRCA2 mutations. *Genetics in Medicine*, **2001**, 3, 422-5	8.1	16
35	Risk of endometrial carcinoma associated with BRCA mutation. *Gynecologic Oncology*, **2001**, 80, 395-8	4.9	135
34	Absence of premalignant histologic, molecular, or cell biologic alterations in prophylactic oophorectomy specimens from BRCA1 heterozygotes. *Cancer*, **2000**, 89, 383-90	6.4	90
33	Genetic prognostic markers for colorectal cancer. *New England Journal of Medicine*, **2000**, 342, 124-5	59.2	24
32	Breast conservation therapy for invasive breast cancer in Ashkenazi women with BRCA gene founder mutations. *Journal of the National Cancer Institute*, **1999**, 91, 2112-7	9.7	149
31	The APCI1307K allele and breast cancer risk. *Nature Genetics*, **1998**, 20, 13-4	36.3	59
30	Involvement of BCL6 in chromosomal aberrations affecting band 3q27 in B-cell non-Hodgkin lymphoma **1998**, 23, 323-327		46
29	Haplotype and phenotype analysis of nine recurrent BRCA2 mutations in 111 families: results of an international study. *American Journal of Human Genetics*, **1998**, 62, 1381-8	11	138
28	A family with three germline mutations in BRCA1 and BRCA2. *Clinical Genetics*, **1998**, 54, 215-8	4	11
27	Chromosomal and Gene Amplification in Diffuse Large B-Cell Lymphoma. *Blood*, **1998**, 92, 234-240	2.2	284
26	Familial Hodgkin's and non-Hodgkin's lymphoma: different patterns in first-degree relatives. *Leukemia and Lymphoma*, **1997**, 27, 503-7	1.9	11
25	New BRCA2 mutation in an Ashkenazi Jewish family with breast and ovarian cancer. *Lancet, The*, **1997**, 350, 117-8	40	14
24	Prevalence of recurring BRCA mutations among Ashkenazi Jewish women with breast cancer. *Genetic Testing and Molecular Biomarkers*, **1997**, 1, 47-51		38
23	Familial colorectal cancer in Ashkenazim due to a hypermutable tract in APC. *Nature Genetics*, **1997**, 17, 79-83	36.3	559
22	Recurrent BRCA2 6174delT mutations in Ashkenazi Jewish women affected by breast cancer. *Nature Genetics*, **1996**, 13, 126-8	36.3	252

21	Low incidence of BRCA2 mutations in breast carcinoma and other cancers. *Nature Genetics*, **1996**, 13, 241-4	36.3	148
20	The carrier frequency of the BRCA2 6174delT mutation among Ashkenazi Jewish individuals is approximately 1%. *Nature Genetics*, **1996**, 14, 188-90	36.3	337
19	BCL6 gene rearrangement and other cytogenetic abnormalities in diffuse large cell lymphoma. *Leukemia and Lymphoma*, **1995**, 20, 85-9	1.9	28
18	Rearrangement of the bcl-6 gene as a prognostic marker in diffuse large-cell lymphoma. *New England Journal of Medicine*, **1994**, 331, 74-80	59.2	339
17	Clusters of chromosome 9 aberrations are associated with clinico-pathologic subsets of non-Hodgkin's lymphoma. *Genes Chromosomes and Cancer*, **1993**, 7, 1-7	5	38
16	Chromosome analysis in the management of patients with non-Hodgkin's lymphoma. *Leukemia and Lymphoma*, **1992**, 7, 275-82	1.9	19
15	Cytogenetic analysis of 434 consecutively ascertained specimens of non-Hodgkin's lymphoma: correlations between recurrent aberrations, histology, and exposure to cytotoxic treatment. *Genes Chromosomes and Cancer*, **1991**, 3, 189-201	5	142
14	Clonal cytogenetic abnormalities in Hodgkin's disease. *Genes Chromosomes and Cancer*, **1991**, 3, 294-9	5	32
13	Small non-cleaved-cell lymphoma (undifferentiated lymphoma, Burkitt's type) in American adults: results with treatment designed for acute lymphoblastic leukemia. *American Journal of Medicine*, **1991**, 90, 328-337	2.4	19
12	Chromosomal Aberrations in Non-Hodgkin Lymphoma: Biologic and Clinical Correlations. *Hematology/Oncology Clinics of North America*, **1991**, 5, 853-869	3.1	57
11	Immunohistochemical, molecular, and cytogenetic analysis of a consecutive series of 20 peripheral T-cell lymphomas and lymphomas of uncertain lineage, including 12 Ki-1 positive lymphomas. *Genes Chromosomes and Cancer*, **1990**, 2, 27-35	5	37
10	18q21 rearrangement in diffuse large cell lymphoma: incidence and clinical significance. *British Journal of Haematology*, **1989**, 72, 178-83	4.5	83
9	Nonrandom chromosomal aberrations are associated with sites of tissue involvement in non-Hodgkin's lymphoma. *Cancer Genetics and Cytogenetics*, **1989**, 37, 85-93		17
8	Genome-wide association studies of cancer predisposition10-20		
7	Inherited rare, deleterious variants in ATM increase lung adenocarcinoma risk		1
6	Common variants in breast cancer risk loci predispose to distinct tumor subtypes		1
5	Polygenic Risk Modelling for Prediction of Epithelial Ovarian Cancer Risk		1
4	Adiposity, metabolites, and colorectal cancer risk: Mendelian randomization study		2

List of Publications

3	Novel Ultra-Rare Exonic Variants Identified in a Founder Population Implicate Cadherins in Schizophrenia	1
2	Fine-mapping of 150 breast cancer risk regions identifies 178 high confidence target genes	2
1	Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses	2